盐酸阿戈美拉汀与盐酸帕罗西汀治疗重症抑郁症的疗效和安全性研究  

Efficacy and Safety of Argometine Hydrochloride and Paroxetine Hydrochloride in Patients with Severe Depression

作　　者：白由竹 BAI You-zhu(The Fourth People′s Hospital of Jiaozuo,Henan Jiaozuo 454000,China)

机构地区：[1]焦作市第四人民医院,河南焦作454000

出　　处：《中国药物评价》2022年第2期180-185,共6页Chinese Journal of Drug Evaluation

摘　　要：目的:研究阿戈美拉汀和帕罗西汀治疗重症抑郁症的疗效,安全性和耐受性。方法:选取医院2017年12月至2019年12月80例诊断为重度抑郁症的患者,依据随机抽签法分为阿戈美拉汀组(40例)与帕罗西汀组(40例)。帕罗西汀组患者接受帕罗西汀20~40 mg·d^(-1),而阿戈美拉汀组患者接受阿戈美拉汀25~50 mg·d^(-1)。通过汉密尔顿抑郁量表(HAM-D17)、汉密尔顿焦虑量表,蒙哥马利-阿斯伯格抑郁量表,希恩残疾量表得分来评估疗效。结果:在治疗后第1周阿戈美拉汀组的MADRS评分明显低于帕罗西汀,差异具有统计学意义(P<0.05);在治疗后第4周阿戈美拉汀组的HAM-A评分、MADRS评分明显低于帕罗西汀组,差异具有统计学意义(P<0.05);阿戈美拉汀组发生皮肤及其附件不良反应的人数明显少于帕罗西汀组,差异具有统计学意义(P<0.05)。阿戈美拉汀组的HAM-D17评分、MADRS评分、HAM-A评分、SDS评分、HAMD-17睡眠评分在治疗后8周内的得分与帕罗西汀组对比,差异无统计学意义(P>0.05)。阿戈美拉汀组在治疗后的第1、2、4、6、8周的显效、有效人数与帕罗西汀组对比,差异无统计学意义(P>0.05)。阿戈美拉汀组在治疗后的第1周、第4周、第8周的CGI-I改善人数、CGI-S评分与帕罗西汀组对比,差异无统计学意义(P>0.05)。结论:阿戈美拉汀在治疗8周后显示出与帕罗西汀等效的抗抑郁药疗效,且安全性可接受。Objective:To study the efficacy,safety and tolerance of agomelatine and paroxetine in Chinese Han patients with severe depression.Methods:A total of 80 patients diagnosed with major depression in our hospital from December 2017 to December 2019 were selected and divided into agomelatine group(40 cases)and paroxetine group(40 cases)according to random drawing method.Patients in the paroxetine group received paroxetine 20 to 40 mg·d^(-1),while patients in the agomelatine group received agomelatine 25 to 50 mg·d^(-1).Efficacy was assessed by ham-D17,Hamilton Anxiety Scale,Montgomery-Asperger Depression Scale,and Sheehan Disability Scale.Results:In the first week after treatment,the MADRS score of agomelatine groupwas significantly lower than that of paroxetine group,the difference was statistically significant(P<0.05).At the fourth week after treatment,the HAM-A score and MADRS score of agomelatine group were significantly lower than those of paroxetine group and MADRS score,the difference was statistically significant(P<0.05).The number of adverse reactions in skin and subcutaneous tissue in agomelatine group was significantly less than that in paroxetine group,the difference was statistically significant(P<0.05).There was no significant difference in the scores of ham-d17,MADRS,HAM-A,SDS and HAMD-17 sleep scores between the two groups within 8 weeks after treatment(P>0.05).There were no statistically significant differences in the number of effective and effective persons in the agomelatine group and the paroxetine group at the 1st,2nd,4th,6th and 8th weeks after treatment(P>0.05).There were no significant differences in the number of CGI-I improvement and CGI-S score between the agomelatine group and the paroxetine group at the 1st,4th and 8th week after treatment(P>0.05).Conclusion:After 8 weeks of treatment,agomelatine shows the same antidepressant effect as paroxetine,and the safety is acceptable.

关 键 词：阿戈美拉汀 帕罗西汀 安全性 重度抑郁症 

分 类 号：R749[医药卫生—神经病学与精神病学]